Phreesia, Inc. (PHR)

Phreesia is a healthcare SaaS and payments platform at an inflection point: it turned cash-flow positive (FY2026 operating cash flow $78.8M; H1 FY2027 $42.3M) and modestly GAAP-profitable, refinanced its acquisition bridge debt into a five-year revolver, and holds a net-cash TTM position — yet revenue growth has cooled to low double digits with the subscription line slightly declining, the Altman Z-Score sits in the distress zone on an accumulated-deficit artifact, interest coverage is thin, and two securities class actions plus a restructuring and a shelf registration temper the picture. Valuation is split: cheap on free-cash-flow yield (~12.3%) and EV/Sales (~1.23x) with a $12 analyst consensus target above the $10.17 quote, but expensive on earnings and the DCF-implied upside looks like aggressive model extrapolation. Overall a mixed but improving fundamental profile.

The Q2 FY2027 print (announced, 2026-09-02) was sold by the tape — the stock tumbled despite a fifth consecutive profitable quarter, maintained guidance and >$23M debt reduction — and a fresh analyst downgrade (2026-09-09) is still being digested, leaving in-window media polarity slightly negative (~-0.08, n=14) with no bullish catalyst to offset it. The sentiment delta is indeterminate (baseline window had no scorable coverage — all law-firm solicitations filtered), and the Red-Flag Screen shows no severe or moderate flags, though a securities class-action overhang persists at law-firm-solicitation level.

Score 2 (weak bearish / bounce-only): price is below every tracked moving average (SMA20 11.36, SMA50 11.22, SMA200 12.06, EMA9 10.71, EMA21 11.12) with MACD negative and falling (line -0.29 vs signal -0.08, histogram -0.22) and ADX 40.81 confirming a strong downtrend. The only positive offsets are oversold oscillator readings (Williams %R -87.7, RSI14 36.9) and a five-session stabilization in the $10.0-10.3 zone; there is no reclaimed moving average and no positive MACD to confirm a bullish turn.